查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
结核病治疗市场 - 2018-2028F 全球行业规模、份额、趋势、机会和预测，按疾病类型、治疗、给药途径、剂型、分销渠道、地区和竞争细分
市场调查报告书
商品编码
1326475

结核病治疗市场 - 2018-2028F 全球行业规模、份额、趋势、机会和预测，按疾病类型、治疗、给药途径、剂型、分销渠道、地区和竞争细分

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Disease Type, By Therapy, By Route of Administration, By Dosage Form, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

由于对寻找新的治疗解决方案来对抗结核病传播和改善患者治疗效果的需求日益增长，全球结核病治疗市场预计在预测期内将以令人印象深刻的速度增长。结核病 (TB) 是一种由结核分枝桿菌引起的高度传染性且可能致命的疾病。它主要影响肺部，但也可以针对身体的其他部位，包括大脑、肾臟和脊柱。根据世界卫生组织 (WHO) 的数据，结核病是全球十大死亡原因之一，预计 2019 年有 1000 万人罹患该病。如此高的发病率，预计对结核病治疗药物的需求继续上升，从而推动预测期内全球结核病治疗市场的增长。

耐药性的增加

结核病是由一种可以迅速突变的细菌引起的，这种细菌会产生难以治疗的耐药菌株。耐多药结核病（MDR-TB）和广泛耐药结核病（XDR-TB）是耐药结核病的两种形式，对全球健康构成重大挑战。结核病耐药菌株的出现增加了对能够有效治疗这些难治菌株的新型结核病治疗药物的需求。反过来，预计这将增加对能够解决与结核病相关的耐药性问题的新型疗法的需求，从而推动未来几年全球结核病治疗市场的增长。在过去的十年中，开发了几种新的结核病药物，包括贝达喹啉、德拉马尼和普托马尼。贝达喹啉是一种新型药物，已被证明可有效对抗耐药结核病，包括耐多药（MDR）和广泛耐药（XDR）结核病。德拉马尼也被证明可以有效对抗耐药结核病，特别是与其他结核病药物联合使用时。 Pretomanid 是这三种药物中最新的一种，已被批准用于治疗广泛耐药结核病。

结核病诊断的进展

诊断工具的进步也改善了结核病的治疗。一个例子是 Xpert MTB/RIF 的使用，这是一种快速分子诊断测试，只需两小时即可检测出结核病和耐药性。另一种诊断工具是 GeneXpert Omni，它可以在 90 分钟内检测出结核病和耐药性。这些工具可以帮助临床医生做出更准确的诊断并为患者选择最合适的治疗方案。结核病诊断方法的发展也带动了有效治疗解决方案的发展，从而为未来几年全球结核病治疗市场的增长开闢了新的前景。

使用联合疗法

多年来，联合疗法在治疗各种慢性和传染病中的使用有所增加，这为新型疗法的增长和开发提供了新的机会。联合疗法的使用在结核病治疗中变得越来越普遍。联合疗法涉及使用多种药物来治疗结核病，这可以改善治疗结果并降低耐药性风险。联合疗法的一个例子是使用贝达喹啉和德拉马尼治疗耐多药结核病。另一种联合疗法称为 BPaMZ 方案，使用贝达喹啉、普托马尼、莫西沙星和吡嗪酰胺药物来治疗药物敏感结核病。联合疗法在结核病治疗中的使用预计将在未来几年推动全球结核病治疗市场的增长。

增加研发活动

近年来，人们重新关注结核病的研究和开发。这导致了新药物和疗法的发现，有可能改善结核病患者的治疗结果。对结核病研究和开发的日益关注也增加了对新型创新结核病治疗方法的需求。根据 ClinicalTrials.gov 的数据，全球约有 1,092 项处于不同开发阶段的研究，旨在开发抗击结核病的治疗方法。

此外，研究仍在寻找较短疗程的有效治疗方法。传统上，结核病治疗涉及长期抗生素疗程，可持续长达两年。然而，最近的研究表明，较短的治疗方案可能同样有效。一个例子是 BPaL 方案的使用，该方案使用贝达喹啉、普托马尼和利奈唑胺药物来治疗耐药结核病。该疗法已被证明可以在短短六个月内有效治疗结核病。反过来，预计这将支持未来几年全球结核病治疗市场的增长。

除了这些新药和新疗法外，研究人员还在探索重新利用现有药物治疗结核病的潜力。例如，2020 年《科学》杂誌上发表的一项研究发现，目前用于治疗肠道感染的一种名为氯硝柳胺的药物在实验室实验中显示出杀死结核分枝桿菌的良好效果。研究人员现在计划进行临床试验，以测试氯硝柳胺治疗人类结核病的有效性。预计这将为未来几年全球结核病治疗市场的增长开闢新的前景。

艾滋病毒感染率不断上升

HIV 是一种攻击帮助身体抵抗任何类型感染的细胞的病毒，使感染 HIV 的患者更容易感染其他疾病和感染。据世界卫生组织称，截至 2021 年，全球约有 3840 万人感染艾滋病毒。由于免疫系统较弱，感染艾滋病毒的人患结核病的风险要高得多。据世界卫生组织称，大约 8% 的结核病病例是艾滋病毒阳性。结核病/艾滋病毒合併感染的高患病率增加了对能够有效治疗这两种疾病的结核病治疗药物的需求，从而支持了全球结核病治疗市场的增长。

最近的发展

  • 2019年，大冢製药有限公司的抗结核新药Pretomanid获得美国食品药品监督管理局（FDA）批准，用于治疗广泛耐药结核病。
  • 葛兰素史克（GSK）有一个结核病药物开发计划，重点开发有效对抗耐药结核病的药物。葛兰素史克目前正在临床试验中测试一种名为 GSK3036656 的药物，该药物在早期研究中已显示出前景。
  • 2019年，美国食品药品监督管理局（FDA）批准了一种名为pretomanid的新药。 Pretomanid 是称为 BPaL 的三药疗法的一部分，该疗法还包括贝达喹啉和利奈唑胺，已被证明对治疗高度耐药的结核病非常有效。在南非进行的一项 III 期试验中，BPaL 方案治癒了 90% 的广泛耐药结核病患者，这种结核病对至少四种主要结核病药物具有耐药性。 BPaL 治疗方案也比以前的耐药结核病护理标准更短，只需六个月而不是长达两年。

可用的定制：

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球结核病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按疾病类型（活动性结核病、潜伏性结核病）
    • 按治疗（一线治疗、二线治疗）
    • 按给药途径（口服、肠胃外、其他）
    • 按剂型（片剂、胶囊、注射剂、其他）
    • 按分销渠道（医院药房、零售药房、网上药房）
    • 按地区
    • 按公司划分 (2022)
  • 产品图
    • 按疾病类型
    • 通过治疗
    • 按给药途径
    • 按剂型分类
    • 按分销渠道
    • 按地区

第 6 章：北美结核病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按疾病类型
    • 通过治疗
    • 按给药途径
    • 按剂型分类
    • 按分销渠道
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲结核病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按疾病类型
    • 通过治疗
    • 按给药途径
    • 按剂型分类
    • 按分销渠道
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 8 章：亚太地区结核病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按疾病类型
    • 通过治疗
    • 按给药途径
    • 按剂型分类
    • 按分销渠道
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 9 章：南美结核病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按疾病类型
    • 通过治疗
    • 按给药途径
    • 按剂型分类
    • 按分销渠道
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲结核病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按疾病类型
    • 通过治疗
    • 按给药途径
    • 按剂型分类
    • 按分销渠道
    • 按国家/地区
  • MEA：国家分析
    • 南非结核病治疗机构
    • 沙特阿拉伯结核病治疗
    • 阿联酋结核病治疗

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：全球结核病治疗市场：SWOT 分析

第 14 章：波特的五力分析

  • 行业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • 商业概览
  • 服务内容
  • 最近的发展
  • 主要人员
  • SWOT分析
    • AstraZeneca
    • Johnson & Johnson
    • Eli Lilly And Company
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer Inc.

第 16 章：战略建议

简介目录
Product Code: 14842

Global Tuberculosis Therapeutics Market is expected to grow at an impressive rate during the forecast period on account of the growing need to find new therapeutic solutions to combat the spread of tuberculosis and improve patient outcomes. Tuberculosis (TB) is a highly infectious and potentially fatal disease caused by the bacteria Mycobacterium tuberculosis. It primarily affects the lungs but can also target other parts of the body, including the brain, kidneys, and spine. According to the World Health Organization (WHO), TB is one of the top 10 causes of death worldwide, with an estimated 10 million people falling ill with the disease in 2019. With such a high incidence rate, the demand for tuberculosis therapeutics is expected to continue to rise, thereby driving the growth of global tuberculosis therapeutics market during the forecast period.

Tuberculosis is a global health issue that affects people of all ages and from all walks of life. Despite the availability of effective treatments, the disease continues to be a major public health concern, particularly in low and middle-income countries. According to the WHO, over 90% of TB cases occur in developing countries, where access to proper healthcare and diagnostic tools is limited. As a result, there is an urgent need for effective, affordable, and accessible TB therapeutics to address the global burden of the disease. This, in turn, is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Additionally, global population is aging, and older adults are more susceptible to TB due to age-related declines in immune function. As the population continues to age, the demand for TB therapeutics that are safe and effective in older adults is expected to increase, thereby driving the growth of global tuberculosis therapeutics market.

Increasing Instances of Drug Resistance

Tuberculosis is caused by a bacterium that can mutate rapidly, leading to drug-resistant strains that are difficult to treat. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are two forms of drug-resistant TB that pose a significant challenge to global health. The emergence of drug-resistant strains of TB has increased the demand for novel TB therapeutics that can effectively treat these difficult-to-treat strains. This, in turn, is expected to increase the demand for novel therapeutics that can address the issue of drug resistance related to tuberculosis, thereby fuelling the growth of global tuberculosis therapeutics market in the coming years. In the past decade, several new TB drugs have been developed, including bedaquiline, delamanid, and pretomanid. Bedaquiline is a novel drug that has been shown to be effective against drug-resistant TB, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Delamanid has also been shown to be effective against drug-resistant TB, particularly when used in combination with other TB drugs. Pretomanid, the newest of the three drugs, has been approved for the treatment of extensively drug-resistant TB.

Advancements in Tuberculosis Diagnostics

Advances in diagnostic tools have also improved the treatment of TB. One example is the use of Xpert MTB/RIF, a rapid molecular diagnostic test that can detect TB and drug resistance in just two hours. Another diagnostic tool is the GeneXpert Omni, which can detect TB and drug resistance in less than 90 minutes. These tools can help clinicians make more accurate diagnoses and choose the most appropriate treatment regimen for their patients. The development in diagnostic methods for tuberculosis is leading to the development of effective therapeutic solutions as well, thereby opening new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Use of Combination Therapies

The use of combination therapies in the treatment of various chronic and infectious diseases has increased over the years, significantly opening new opportunities for the growth and development of novel therapeutics. The use of combination therapies is becoming increasingly common in the treatment of TB. Combination therapies involve the use of multiple drugs to treat TB, which can improve treatment outcomes and reduce the risk of drug resistance. One example of combination therapy is the use of bedaquiline and delamanid in the treatment of MDR-TB. Another combination therapy, called the BPaMZ regimen, uses the drugs bedaquiline, pretomanid, moxifloxacin, and pyrazinamide to treat drug-sensitive TB. The use of combination therapies in the treatment of tuberculosis is expected to drive the growth of global tuberculosis therapeutics market in the coming years.

Increased Research and Development Activities

In recent years, there has been a renewed focus on TB research and development. This has led to the discovery of new drugs and therapies that have the potential to improve treatment outcomes for patients with TB. The increased focus on TB research and development has also increased the demand for new and innovative TB therapeutics. According to clinicaltrials.gov, there are around 1,092 studies in different phases of development across the globe for developing a treatment for combating tuberculosis.

Additionally, studies are going on to find effective treatments with shorter regimens. Traditionally, TB treatment has involved a long course of antibiotics that can last for up to two years. However, recent research has shown that shorter treatment regimens may be just as effective. One example is the use of the BPaL regimen, which uses the drugs bedaquiline, pretomanid, and linezolid to treat drug-resistant TB. This regimen has been shown to be effective in treating TB in as little as six months. This, in turn, is expected to support the growth of global tuberculosis therapeutics market in the coming years.

In addition to these new drugs and regimens, researchers are also exploring the potential of repurposing existing drugs for the treatment of TB. For example, a study published in the journal Science in 2020 found that a drug called niclosamide, which is currently used to treat intestinal infections, showed promising results in killing Mycobacterium tuberculosis in laboratory experiments. The researchers are now planning to conduct clinical trials to test niclosamide's effectiveness in treating TB in humans. This is further expected to open new prospects for the growth of global tuberculosis therapeutics market in the coming years.

Growing Prevalence of HIV

HIV is a virus that attacks cells that help the body fight any kind of infection, making the patient suffering from HIV more vulnerable to other diseases and infections. According to WHO, as of 2021, there are around 38.4 million people living with HIV worldwide. People who are infected with HIV are at a much higher risk of developing TB due to their weakened immune systems. According to the WHO, around 8% of all TB cases are HIV-positive. The high prevalence of TB/HIV co-infection has increased the demand for TB therapeutics that can effectively treat both diseases, thereby supporting the growth of global tuberculosis therapeutics market.

Market Segmentation

Global Tuberculosis Therapeutics Market can be segmented by disease type, therapy, route of administration, dosage form, distribution channel, and by region. Based on disease type, global tuberculosis therapeutics market can be split into active tuberculosis and latent tuberculosis. By therapy, the global tuberculosis therapeutics market can be divided into first-line therapy and second-line therapy. Based on the route of administration, global tuberculosis therapeutics can be categorized into oral, parenteral, and others. By dosage form, the global tuberculosis therapeutics market can be segmented into tablets, capsules, injections, and others. In terms of distribution channels, the global tuberculosis therapeutics market can be grouped into hospital pharmacy, retail pharmacy, and online pharmacy. Regionally, the global tuberculosis therapeutics market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

AstraZeneca, Plc., Johnson & Johnson, Eli Lilly And Company, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi SA, Novartis AG, Sun Pharmaceutical Industries Ltd., Pfizer Inc., among others, are some of the leading players operating in the global Tuberculosis Therapeutics market.

Recent Developments

  • In 2019, Otsuka Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for a new TB drug, Pretomanid, for the treatment of extensively drug-resistant TB.
  • GlaxoSmithKline (GSK), which has a TB drug development program focused on developing drugs that are effective against drug-resistant TB. GSK is currently testing a drug called GSK3036656 in clinical trials, which has shown promise in early studies.
  • In 2019, the US Food and Drug Administration (FDA) approved a new drug called pretomanid. Pretomanid is part of a three-drug regimen called BPaL, which also includes bedaquiline and linezolid, which has been shown to be highly effective in treating highly drug-resistant forms of TB. In a phase III trial conducted in South Africa, the BPaL regimen cured 90% of patients with extensively drug-resistant TB, a form of TB that is resistant to at least four of the main TB drugs. The BPaL regimen is also shorter than the previous standard of care for drug-resistant TB, taking just six months instead of up to two years.

Report Scope:

In this report, Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

  • Active Tuberculosis
  • Latent Tuberculosis

Tuberculosis Therapeutics Market, By Therapy:

  • First Line Therapy
  • Second Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Tuberculosis Therapeutics Market, By Therapy:

  • First Line Therapy
  • Second Line Therapy

Tuberculosis Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Tuberculosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Active Tuberculosis, Latent Tuberculosis)
    • 5.2.2. By Therapy (First Line Therapy, Second Line Therapy)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Disease Type
    • 5.3.2. By Therapy
    • 5.3.3. By Route of Administration
    • 5.3.4. By Dosage Form
    • 5.3.5. By Distribution Channel
    • 5.3.6. By Region

6. North America Tuberculosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy
    • 6.2.3. By Route of Administration
    • 6.2.4. By Dosage Form
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By Dosage Form
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By Dosage Form
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By Dosage Form
        • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy
    • 7.2.3. By Route of Administration
    • 7.2.4. By Dosage Form
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Tuberculosis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Dosage Form
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Tuberculosis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Dosage Form
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Tuberculosis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Dosage Form
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Tuberculosis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By Dosage Form
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By Dosage Form
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy
    • 8.2.3. By Route of Administration
    • 8.2.4. By Dosage Form
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Tuberculosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Dosage Form
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Tuberculosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Dosage Form
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Dosage Form
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Dosage Form
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Dosage Form
        • 8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy
    • 9.2.3. By Route of Administration
    • 9.2.4. By Dosage Form
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Dosage Form
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Dosage Form
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Dosage Form
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy
    • 10.2.3. By Route of Administration
    • 10.2.4. By Dosage Form
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Dosage Form
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Dosage Form
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Tuberculosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Dosage Form
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Service Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. AstraZeneca
    • 15.5.2. Johnson & Johnson
    • 15.5.3. Eli Lilly And Company
    • 15.5.4. Mylan N.V.
    • 15.5.5. Teva Pharmaceutical Industries Ltd.
    • 15.5.6. Sanofi SA
    • 15.5.7. Novartis AG
    • 15.5.8. Sun Pharmaceutical Industries Ltd.
    • 15.5.9. Pfizer Inc.

16. Strategic Recommendations